

## ASX ANNOUNCEMENT

# Results of 2022 Annual General Meeting

**24 November 2022, Melbourne, Australia:**

The Board of Exopharm Limited (ASX:EX1) ("Exopharm" or the "Company") is pleased to advise that shareholders of the Company passed all Resolutions at today's Annual General Meeting by way of poll.

In accordance with ASX Listing Rule 3.13.2 and Section 251AA(2) of the Corporations Act 2001 (Cth), a summary of the proxy votes and the number of votes cast on each resolution in the poll is attached.

*By the Company Secretary - this announcement has been authorised for release by the Company Secretary, Mr David Franks, on behalf of the Board.*

### [COMPANY AND MEDIA ENQUIRIES:](#)

Join our mailing list to receive updates:

<http://exo.ph/ExoMails>

[www.exopharm.com](http://www.exopharm.com)

P: +61 (0)3 9111 0026

Ian Dixon

Managing Director

Tel: +61 418 561 907

[ian.dixon@exopharm.com](mailto:ian.dixon@exopharm.com)

### [ABOUT EXOPHARM](#)

Exopharm (ASX:EX1) is a leader in advancing Genetic Medicines and other exosome-based medicines using exosomes or extracellular vesicles (EVs) as a chassis for improved and non-viral drug-delivery.

Exopharm (ASX:EX1) is pursuing a product pipeline-driven platform strategy. Exosomes can be loaded with a variety of active pharmaceutical ingredients (APIs) and can be targeted to selected cell-types and tissue types, improving the safety-profile of the APIs and providing better treatments. Exosomes can be used to deliver small molecule drugs, mRNA, DNA and other types of APIs.

Exosomes are an alternative means of drug-delivery inside the body, alongside technologies such as lipid nanoparticles (LNP), cell-penetrating peptides, viral vectors and liposomes.

Exopharm's exosome technologies solve important needs for the success of exosome medicines – **LEAP** manufacturing technology, **LOAD** API loading technologies and **EVPS** tropism technologies.

Exosome-based medicines could improve the treatment of many chronic or inherited medical conditions.

Exopharm is making its proprietary technologies available to pharmaceutical and biotechnology companies that want to harness exosome-delivery for their own products. In addition, Exopharm is using its technology platform to enable its own product development programs - each aimed at delivering a transformative medicine for an unmet medical need.

### [FORWARD LOOKING STATEMENTS](#)

This announcement contains forward-looking statements which incorporate an element of uncertainty or risk, such as 'intends', 'may', 'could', 'believes', 'estimates', 'targets', 'aims', 'plans' or 'expects'. These statements are based on an evaluation of current corporate estimates, economic and operating conditions, as well as assumptions regarding future events. These events are, as at the date of this announcement, expected to take place, but there cannot be any guarantee that such events will occur as anticipated or at all given that many of the events are outside of Exopharm's control or subject to the success of the Development Program. Furthermore, the Company is subject to several risks as disclosed in the Prospectus dated 6 November 2018.

# Disclosure of Proxy Votes

## Exopharm Limited

Annual General Meeting

Thursday, 24 November 2022



**Automic**

GPO Box 5193, Sydney, NSW 2001

P 1300 288 664 (aus) or +61 (0)2 9698 5414 (world)

F +61 (0)2 8583 3040 E [hello@automic.com.au](mailto:hello@automic.com.au)

ABN 27 152 260 814

In accordance with section 251AA of the Corporations Act 2001, the following information is provided in relation to resolutions put to members at the meeting.

Resolution	Decided by Show of Hands (S) or Poll (P)	Total Number of Proxy Votes exercisable by proxies validly appointed	Proxy Votes				Poll Results (if applicable)		
			FOR	AGAINST	ABSTAIN	PROXY'S DISCRETION	FOR	AGAINST	ABSTAIN
1 Adoption of Remuneration Report	P	22,299,330	21,887,521 98.15%	275,309 1.23%	4,694	136,500 0.61%	23,387,021 98.84%	275,309 1.16%	4,694
2 Re-Election of Mr Jason Watson as Director	P	50,587,957	50,302,539 99.44%	148,918 0.29%	4,694	136,500 0.27%	51,802,039 99.71%	148,918 0.29%	4,694
3 Adoption of New Constitution	P	50,577,957	50,417,539 99.68%	23,918 0.05%	14,694	136,500 0.27%	51,917,039 99.95%	23,918 0.05%	14,694
4 Adoption of Proportional Takeover Provisions	P	50,577,957	50,292,539 99.44%	166,918 0.33%	14,694	118,500 0.23%	51,774,039 99.68%	166,918 0.32%	14,694

